ISRCTN72444640已完成未知
Evaluation of late clinical events after drug-eluting versus bare-metal stents in patients at risk: BAsel Stent Kosten Effektivitäts Trial - PROspective Validation Examination
niversity Hospital Basel (Switzerland)0 个研究点目标入组 2,400 人开始时间: 2007年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 2,400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. All comers, 24 hours a day, seven days a week, irrespective of indication for Percutaneous Coronary Intervention (PCI)
- •2. With the need for large (more than or equal to 3.0 mm stents only) native vessel stenting
排除标准
- •1. In-stent-restenosis
- •2. Bypass graft disease
- •3. Main stem disease to be stented
- •4. Cardiogenic shock
- •5. Planned surgery within the next six months
- •6. Oral anticoagulation needed (artificial heart valves, atrial fibrillation)
- •7. No compliance expected
- •8. Enrolled in another study
- •9. No consent
研究者
相似试验
已完成
4 期
Safety and Efficacy Study Comparing 3 New Types of Coronary StentsCoronary ThrombosisCoronary Artery DiseaseNCT01166685University Hospital, Basel, Switzerland2,291
终止
不适用
Beta-lactam pharmacokinetics in haematology patients with sepsis.Febrile neutropeniaHaematological malignancySepsisACTRN12618000110280Cancer Care Services, RBWH100
已完成
不适用
Evaluation of the Effects of Medicaments Used After Free Gingival Graft on Postoperative Complications.Pain, PostoperativeHealing WoundHemorrhageAnalgesiaNCT05386667Pamukkale University60
尚未招募
不适用
Evaluating the impact of a pre-discharge medication review service on preventing hospital re-admissions in high risk patients-a pilot study.Medication misadventurePoly-PharmacyCo-morbiditiesAdverse drug reactionsPoor compliancePublic Health - Health service researchACTRN12615000746538niversity of Tasmania226
未知
3 期
A Clinical Pharmacology and Long Term Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With Type 1 Diabetes Who Have Inadequate Glycemic ControlType 1 Diabetes MellitusJPRN-jRCT2080223107AstraZeneca